T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

(MedPage Today) -- CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab...

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--May 31, 2025-

At ASCO, Enhertu cements growing role in stomach cancer care

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its importance as a second-line treatment option.

HER2-Targeted Therapy Extends Gastric Cancer Survival: ASCO 2025

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and GEJA after first-line treatment failure.

T-DXd Earns Second-Line SOC for HER2+ Gastric/GEJ Cancer

T-DXd led to improvements in OS, PFS, ORR, and DOR compared with ramucirumab/paclitaxel in the second line for HER2-positive gastric and GEJ cancer.

Enhertu extends life by three months for some stomach cancer patients, study finds

CHICAGO — For AstraZeneca and Daiichi Sankyo, the antibody drug conjugate Enhertu has become a recurring topic at the annual American Society of Clinical Oncology meeting. Their latest data presented Saturday showed that previously treated ...